Demographics of the primary panel used for the PPTP in vitro testing

Cell Line	Diagnosis		Treatment	Site of specimen	Age at Dx	Gender
	Rhabdomyosarcoma
RD	Embryonal		Post-Tx*	muscle	7	F
Rh41	Alveolar		Post-Tx	lung		F
Rh18	Embryonal		DX§	perineum	2
Rh30	Alveolar		DX	bone marrow	16	M
	Brain Tumor
BT-12	Atypical teratoid/rhabdoid		DX
SJ-GBM2	Glioblastoma multiforme		Post-Tx	brain	5	F
CHLA-266	Atypical teratoid/rhabdoid		DX	posterior fossa	1.5	F
	Ewings Family of Tumors (EFT)
CHLA-9	PNET		DX	thorax	14	F
CHLA-10	PNET		Post-TX	thorax	14	F
CHLA-258	PNET		Post-BMT**	lung	12	F
TC-71	Ewings		Post-Tx	bone marrow	22	M
	Neuroblastoma	MYCN status†
NB-1643	Neuroblastoma	A	DX	adrenal mass	<3
NB-EBc1	Neuroblastoma	NA	Post-Tx	retroperitoneal mass	<3
CHLA-90	Neuroblastoma	NA	Post-BMT	bone marrow	8	M
CHLA-136	Neuroblastoma	A	Post-BMT	blood	3	F
	Leukemia
NALM-6	Pre-B cell ALL		Post-Tx*	peripheral blood	19	M
RS4;11	Pre-B cell ALL		Post-Tx	bone marrow	32	F
COG-LL-317	T-cell ALL		Post-Tx	bone marrow	1.7	M
MOLT-4	T-cell ALL		Post-Tx	peripheral blood	19	M
CCRF-CEM	T-cell ALL		Post-Tx	peripheral blood	4	F
Kasumi-1	AML		Post-BMT**	peripheral blood	7	M
	Lymphoma
Karpas-299	Anaplastic Large Cell		Post-Tx	peripheral blood	25	M
Ramos-RA1	Burkitt's			peripheral blood	3	M

* Cell line established from patients at relapse following chemotherapy.
** Cell line established from patients at relapse following myeloablative chemotherapy supported by bone marrow transplantation.

§ Cell line established from patient at diagnosis prior to treatment.
† Genomic amplification of MYCN; A: amplified, NA: not amplified.